HYEX HEALTHY EXTRACTS INC.

OTC Medicinal Chemicals & Botanical Products NV CIK: 0001630176
AI RATING
STRONG_SELL
85% Confidence

Investment Thesis

Despite exceptional 2245% revenue growth and healthy 53.7% gross margins, the company's core operations are severely unprofitable at -73.7% operating margin. The 20.1M net income with zero YoY growth appears driven by non-operating items rather than sustainable operations. Critical liquidity constraints (0.79x current ratio, only 146.9K cash) combined with negative operating cash breakeven create acute financial distress.

Strengths

  • + Exceptional YoY revenue growth of 2245.7% demonstrates strong market demand and commercial traction
  • + Healthy gross margin of 53.7% indicates product-market fit and pricing power
  • + Low debt-to-equity ratio of 0.03x minimizes financial leverage and default risk

Risks

  • ! Operating margin of -73.7% reveals core business is fundamentally unprofitable despite revenue growth
  • ! Critical liquidity crisis with current ratio 0.79x and minimal 146.9K cash reserves creates solvency risk
  • ! Net income of 20.1M with 0.0% YoY growth indicates reliance on non-operating items, not operational profitability
  • ! Interest coverage ratio of -41.6x shows inability to service debt from operational earnings
  • ! Zero insider buying activity in 90 days suggests management lacks confidence in fundamentals

Key Metrics to Watch

Financial Metrics

Revenue
4.5M
Net Income
20.1M
EPS (Diluted)
$0.00
Free Cash Flow
165.5K
Total Assets
27.8M
Cash
146.9K

Profitability Ratios

Gross Margin 53.7%
Operating Margin -73.7%
Net Margin 446.0%
ROE 83.7%
ROA 72.3%
FCF Margin 3.7%

Balance Sheet & Liquidity

Current Ratio
0.79x
Quick Ratio
0.29x
Debt/Equity
0.03x
Debt/Assets
13.6%
Interest Coverage
-41.57x
Long-term Debt
641.9K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-11T12:27:25.150350 | Data as of: 2025-12-31 | Powered by Claude AI